Free Trial

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 0.8% - Should You Sell?

Eupraxia Pharmaceuticals logo with Medical background

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) shares traded down 0.8% during trading on Thursday . The stock traded as low as $3.89 and last traded at $3.94. 9,469 shares traded hands during trading, a decline of 28% from the average session volume of 13,195 shares. The stock had previously closed at $3.97.

Analyst Upgrades and Downgrades

Separately, Craig Hallum assumed coverage on shares of Eupraxia Pharmaceuticals in a research note on Friday, February 21st. They issued a "buy" rating and a $12.00 price objective for the company.

Get Our Latest Stock Analysis on EPRX

Eupraxia Pharmaceuticals Trading Down 0.8%

The stock has a fifty day moving average price of $3.64 and a 200 day moving average price of $3.47. The firm has a market cap of $141.25 million, a price-to-earnings ratio of -5.47 and a beta of 0.66.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). On average, sell-side analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.67 EPS for the current year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in shares of Eupraxia Pharmaceuticals during the 4th quarter worth about $31,000. Raymond James Financial Inc. bought a new position in Eupraxia Pharmaceuticals in the 4th quarter worth approximately $37,000. Bank of Montreal Can increased its position in Eupraxia Pharmaceuticals by 15.2% in the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock worth $178,000 after buying an additional 7,500 shares during the period. Royal Bank of Canada raised its position in shares of Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock valued at $1,125,000 after buying an additional 59,683 shares during the last quarter. Finally, Scotia Capital Inc. lifted its position in shares of Eupraxia Pharmaceuticals by 11.6% in the 1st quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company's stock worth $5,072,000 after acquiring an additional 160,960 shares during the period.

About Eupraxia Pharmaceuticals

(Get Free Report)

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eupraxia Pharmaceuticals Right Now?

Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.

While Eupraxia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines